Zhitong Finance App News, Fu Hong Han Lin (02696.HK) issued an announcement. Recently, the application for a phase 1 clinical trial (IND) for the treatment of various solid tumors was approved by the US Food and Drug Administration (FDA) for the treatment of various solid tumors, the Navulidumab biosimilar drug HLX18 (recombinant anti-PD-1 anthropogenic monoclonal antibody injection) (HLX18) independently developed by the company. The company plans to conduct relevant phase 1 clinical trials in the US when conditions are met.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Fu Hong Han Lin (02696.HK) issued an announcement. Recently, the application for a phase 1 clinical trial (IND) for the treatment of various solid tumors was approved by the US Food and Drug Administration (FDA) for the treatment of various solid tumors, the Navulidumab biosimilar drug HLX18 (recombinant anti-PD-1 anthropogenic monoclonal antibody injection) (HLX18) independently developed by the company. The company plans to conduct relevant phase 1 clinical trials in the US when conditions are met.